Bethanechol Chloride

Cholinergic Agonist Parasympathomimetic (Muscarinic Agonist)

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 5-25 mg/dog (or 0.5-1 mg/kg) q8h Duration: As needed for clinical effect
Notes: Administer on an empty stomach to reduce nausea. Titrate dose to effect.
Dog SC 0.05-0.1 mg/kg q8h Duration: As needed
Notes: Use only if oral route is not feasible. Do not give IM or IV.
Cat PO 1.25-5 mg/cat (or 0.5-1 mg/kg) q8h Duration: As needed
Notes: Start at low end and titrate. Administer on empty stomach.
Cat SC 0.05-0.1 mg/kg q8h Duration: As needed
Notes: For acute management of bladder atony.
Horse PO 0.05-0.1 mg/kg q6-8h Duration: As needed
Notes: Use with caution; monitor for colic.
Horse SC 0.02-0.04 mg/kg q6-8h Duration: As needed
Notes: For postoperative ileus.
Cattle SC 0.02-0.05 mg/kg q12h Duration: As needed
Notes: Off-label; use with caution in ruminants due to risk of ruminal tympany.
Small Ruminants SC 0.02-0.05 mg/kg q12h Duration: As needed
Notes: Off-label; monitor for adverse effects.
Rabbit PO 0.1-0.5 mg/kg q8-12h Duration: As needed
Notes: Off-label; use with caution in rabbits due to risk of GI stasis.
Reptiles PO 0.02-0.05 mg/kg q24h Duration: As needed
Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications
  • Stimulation of gastrointestinal motility
  • Stimulation of urinary bladder contraction
Dog (Canine)
  • Treatment of gastric atony
  • Treatment of urinary bladder atony (non-obstructive)
  • Management of megacolon (adjunctive)
  • Treatment of esophageal reflux (off-label)
Cat (Feline)
  • Treatment of urinary bladder atony (non-obstructive)
  • Management of megacolon (adjunctive)
  • Treatment of gastric atony
Horse (Equine)
  • Treatment of postoperative ileus
  • Treatment of gastric atony
  • Treatment of urinary bladder atony (off-label)
Cattle (Bovine)
  • Treatment of ruminal atony (off-label)
  • Treatment of urinary bladder atony (off-label)
Small Ruminants (Sheep / Goat)
  • Treatment of ruminal atony (off-label)
  • Treatment of urinary bladder atony (off-label)
Rabbit & Small Mammals
  • Treatment of gastrointestinal stasis (off-label)
  • Treatment of urinary bladder atony (off-label)
Exotic & Other Species
  • Treatment of gastrointestinal stasis in reptiles (off-label)
  • Treatment of urinary bladder atony in small mammals (off-label)

Pharmacology & Mechanism of Action

Drug Class: Cholinergic Agonist | Pharmacological Group: Parasympathomimetic (Muscarinic Agonist)

Mechanism of Action: Bethanechol chloride is a synthetic choline ester that directly stimulates muscarinic acetylcholine receptors, producing parasympathomimetic effects. It has negligible nicotinic activity, thus its primary actions are on the gastrointestinal and urinary tracts. It increases gastrointestinal motility, tone, and secretions, and stimulates detrusor muscle contraction and relaxation of the trigone and sphincter, promoting bladder emptying.

Pharmacodynamics: Bethanechol acts directly on muscarinic receptors, mimicking the effects of acetylcholine. It enhances gastric emptying, intestinal peristalsis, and lower esophageal sphincter tone. In the urinary bladder, it increases detrusor muscle contractility and decreases bladder capacity, facilitating micturition. It also stimulates salivary, gastric, and pancreatic secretions. Its effects are more pronounced on the gastrointestinal and urinary systems than on the cardiovascular system due to its selectivity for muscarinic receptors.

⚑ Pharmacokinetics Summary

Absorption: Bethanechol is poorly absorbed after oral administration; onset of action is 30-90 minutes. Subcutaneous administration results in more reliable absorption and onset within 5-15 minutes.
Distribution: Widely distributed in body tissues; crosses the blood-brain barrier poorly. It is not known to cross the placenta in significant amounts.
Metabolism: Resistant to hydrolysis by acetylcholinesterase, thus has a longer duration of action than acetylcholine. It is metabolized by nonspecific esterases in the liver and plasma.
Excretion: Excreted primarily in the urine, both as unchanged drug and metabolites.
Half-Life: Approximately 1-2 hours in dogs and cats; duration of action is 1-2 hours after subcutaneous administration and up to 6 hours after oral administration.
Bioavailability: Oral bioavailability is low (approximately 10-20%) due to poor absorption and first-pass metabolism.
Protein Binding: Low; less than 20% bound to plasma proteins.

Available Formulations & Strengths

Oral Tablet 5 mg, 10 mg, 25 mg, 50 mg (PO)
Injectable Solution 5 mg/mL (SC)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to bethanechol or any component
  • Mechanical gastrointestinal or urinary obstruction
  • Peptic ulcer disease
  • Hyperthyroidism
  • Asthma or bronchial hyperreactivity
  • Cardiac disease (bradycardia, hypotension)
  • Epilepsy or seizure disorders
  • Recent gastrointestinal or bladder surgery (risk of rupture)
  • Peritonitis
  • Pregnancy (unless benefits outweigh risks)
Warnings & Clinical Precautions:
  • Do not administer IM or IV; severe cholinergic effects may occur.
  • Use with caution in animals with a history of asthma, COPD, or other respiratory conditions.
  • Monitor for signs of cholinergic toxicity (salivation, lacrimation, urination, defecation, emesis).
  • Use with caution in animals with bradycardia or hypotension.
  • In food animals, observe withdrawal times.
  • Ensure adequate hydration before use.
  • May cause abdominal cramps and diarrhea; adjust dose if necessary.

Adverse Effects & Reactions

Common:

  • Salivation
  • Lacrimation
  • Diarrhea
  • Vomiting
  • Abdominal cramps
  • Increased urination
  • Sweating (in horses)

Serious / Severe:

  • Bronchospasm
  • Severe bradycardia
  • Hypotension
  • Cardiac arrest
  • Seizures
  • GI perforation (if obstruction present)

Rare:

  • Allergic reactions
  • Urinary incontinence
  • Muscle tremors

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Anticholinergics (atropine, glycopyrrolate) Antagonize the effects of bethanechol; may be used as antidote. High
Procainamide May antagonize the effects of bethanechol on the heart. Moderate
Ganglionic blocking agents (e.g., hexamethonium) May potentiate cholinergic effects. Moderate
Cholinesterase inhibitors (e.g., neostigmine) Additive cholinergic effects; increased risk of toxicity. High
Beta-blockers May enhance bradycardic effects. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Excessive salivation
  • Lacrimation
  • Urination
  • Defecation
  • Vomiting
  • Diarrhea
  • Bronchospasm
  • Bradycardia
  • Hypotension
  • Muscle weakness
  • Seizures
  • Respiratory depression

Emergency Treatment Protocol: Discontinue drug immediately. Administer atropine sulfate (0.02-0.04 mg/kg IV, IM, or SC) as an antidote, repeated as needed to control cholinergic signs. Provide supportive care: maintain airway, administer oxygen, and manage seizures with diazepam if necessary. Monitor cardiac and respiratory function. In severe cases, consider fluid therapy and vasopressors for hypotension.

Food Animal Withdrawal Times

πŸ₯© Meat: 7 daysπŸ₯› Milk: 3 days

Withdrawal times are not established for bethanechol in food animals; consult regulatory guidelines. A conservative withdrawal period of at least 7 days for meat and 3 days for milk is recommended.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25Β°C, excursions permitted to 15-30Β°C).

Handling & Special Conditions: Protect from moisture. Keep container tightly closed.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not FDA-approved for veterinary use, but may be used legally in animals under extra-label regulations.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is permitted under AMDUCA with a valid veterinary-client-patient relationship, provided withdrawal times are extended and residues are avoided. In non-food animals, extra-label use is common.

Clinical Pearls & Practice Notes

πŸ’‘ Clinical Insights: Bethanechol is a direct-acting muscarinic agonist used primarily to manage non-obstructive urinary bladder atony and gastrointestinal motility disorders in small animals. It is most effective when administered subcutaneously for acute effects, but oral administration is more convenient for chronic therapy. Response is variable; dose titration is essential. It should not be used in cases of mechanical obstruction. Atropine should be available as an antidote. In horses, it is used off-label for postoperative ileus, but careful monitoring is required due to risk of colic. In ruminants, use is limited due to potential for ruminal tympany. Always rule out obstruction before use. Monitor for cholinergic side effects and adjust dose accordingly.

References & Literature

  • πŸ“š Plumb's Veterinary Drug Handbook
  • πŸ“š Papich Veterinary Pharmacology and Therapeutics
  • πŸ“š Compendium of Veterinary Products (CVP)